Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

15 February 2012 CSL Behring Announces 2012 Interlaken Leadership Awards Recipients

CSL Behring announced today the four recipients of the 2012 Interlaken Leadership Awards. Now in its second year, the Interlaken Leadership Awards program recognizes scientists whose proposals are likely to advance innovative medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders. The total value of the four awards is estimated to be more than $1 million USD.

> Read More
06 February 2012 U.S. Senate Declares May 16, 2012 as Hereditary Angioedema Awareness Day

The U.S. Hereditary Angioedema Association (HAEA) announced today that the United States Senate has unanimously passed a resolution (S. Res. 286) recognizing May 16, 2012, as Hereditary Angioedema (HAE) Awareness Day. The resolution, offered by Senator Daniel Inouye (D-Hawaii) and Senator Saxby Chambliss (R-Georgia), is the result of a year-long political advocacy effort to generate recognition of the significant need for increased professional education regarding HAE, a rare and potentially fatal genetic disorder, and to highlight the need for further research aimed at improving diagnosis and treatment options for patients.

> Read More
02 February 2012 International Phase I Trial Results of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) Show All Pharmacokinetic Parameters Significantly Improved in Patients with Severe Hemophilia B

CSL Behring today announced the results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B. Results of the study, which were presented during an oral session at the Gesellschaft für Thrombose- und Hämostaseforschung e.V. (GTH) congress in Switzerland, showed that rIX-FP was well tolerated in all patients and lasted longer in the body, due to its prolonged half-life, compared with current Factor IX treatment options.

> Read More
12 January 2012 First clinical trial site initiated in CSL Behring Phase II/III pivotal study of recombinant fusion protein linking coagulation factor IX with recombinant albumin

CSL Behring has announced that the first site has been initiated in its global phase II/III, multi-center study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The site is located in Vienna, Austria. The prospective, open-label study will enroll adolescents and adults (12 – 65 years) who have hemophilia B. CSL Behring, in collaboration with its parent company, CSL Limited (ASX:CSL), is developing rIX-FP for the prophylaxis and treatment of bleeding episodes in patients with congenital Factor IX (FIX) deficiency as part of the PROLONG-9FP clinical study program.

> Read More
03 January 2012 CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema

CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert®, C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder. With appropriate training from a physician, patients can now self-administer Berinert by intravenous infusion. As part of the label expansion, Berinert is now also indicated to treat life-threatening laryngeal HAE attacks, as well as facial and abdominal attacks.

> Read More
Page 26 of 50 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+